Impact of Objective Sleep Duration on Blood Glucose Control in Type 1 Diabetes Adult Patients

University Hospital, Grenoble79 enrolled

Overview

The objective of this study is to assess the impact of objective sleep duration on blood glucose control in type 1 diabetes adult patients. This study will also evaluate the impact of objective sleep duration on blood pressure over a 24-hour period and the impact of objective sleep duration on quality of life. Last, it will investigate the influence of objective physical activity duration on blood glucose control, blood pressure and quality of life. This study will enrol ambulatory patients only. On day 0, patients receive an actimeter and an ambulatory blood pressure monitoring device. The actimeter measures activity and sleep duration. The patient keeps the actimeter for 3 consecutive days and the blood pressure monitoring device for 24 hours. A blood sample is also collected. Patients will be divided into 2 groups, based on objective sleep duration: 'short-sleepers' and 'long-sleepers'. The threshold will be the median of the total population. HbA1c will be compared between the 2 groups with a Student test or a Mann-Whitney test, depending on the normality of distribution. A model of multiple linear regression will be created. HbA1c will be entered as dependant variable and objective sleep duration as independent variable Patients will be divided into 2 groups, based on objective activity duration: 'low-activity' and 'high-activity'. The threshold will be the median of the total population. HbA1c, blood pressure, quality of life, biological results and general characteristics will be compared between the 2 groups with a Student test or a Mann-Whitney test, depending on the normality of distribution. Qualitative variables will be studied with a chi-square test.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Type 1 Diabetes

Interventions

Actimeter + blood pressure monitoringDEVICE

Patients will receive an actimeter that they will wear for 3 days and an ambulatory blood pressure monitoring device that they will keep for 24 hours.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient affiliated to Social Security * Written consent to participate to the study * Ambulatory medical follow-up * Patient with type 1 diabetes, defined by the criteria of the American Diabetes Association in 1997, stable (no ketoacidosis episode or hypoglycaemia with loss of consciousness requiring the intervention of a third person, during the previous month) Exclusion Criteria: * Underage patient, major patient under guardianship or protected by the Law * Pregnant, parturient or breastfeeding woman * Person with no freedom (prisoner), person hospitalized without consent and not protected by the Law * Non-stabilized diabetes with at least one ketoacidosis episode or hypoglycaemia with loss of consciousness requiring the intervention of a third person, during the previous month. * Bedridden person or person with mobility impairment. * Patient already hospitalized at enrolment time * Patient whose physical or psychological health could interfere with obtention of informed consent and compliance to the protocol (especially answers to the questionnaires) * Terminally-ill patient

Locations (1)

Service de Diabétologie du Pr Halimi, CHU

Grenoble, France

Outcomes

Primary Outcomes

HbA1c in %

Time frame: Day 0 or Day 3

Secondary Outcomes

Objective sleep duration in minutes

Time frame: Day 0 to Day 3

Blood pressure in cm Hg

Time frame: Day 0, 24 hours

Quality of life assessed through questionnaire

Time frame: Day 0 to Day 3

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.